Regen BioPharma, Inc. to Present at the Emerging Growth Conference on September 6, 2023
Regen BioPharma, Inc. cordially invites both individual and institutional investors, advisors, and analysts to participate in its live and engaging presentation at the Emerging Growth Conference.
Regen BioPharma, Inc., a biotech firm working on various groundbreaking projects in the field of cellular therapies, RNA vaccines, RNA and DNA therapeutics, and small molecule drugs, is set to participate in the upcoming Emerging Growth Conference. The event will take place on September 6, 2023, and you can find more information about it at https://emerginggrowth.com/conference/.
In this exciting online event, shareholders and investors will have the chance to engage with the Company's CEO, Dr. David Koos, in a live and interactive environment. Feel free to ask your queries during the event, and Dr. Koos and his team will make every effort to answer as many of them as they can.
Dr. David Koos, the Company's CEO and Chairman, stated that they intend to utilize this period to converse about their latest patent submission. The submission unveils innovative strategies for producing CAR-T cells specifically devised to combat autoimmunity. Additionally, they will address any queries raised by shareholders.
Regen BioPharma, Inc. has scheduled a presentation from 3:55 to 4:05 Eastern time on Wednesday, September 6, 2023. To secure your attendance at the conference and receive any forthcoming announcements, kindly register at this link: https://goto.webcasts.com/starthere.jsp?ei=1603285&tp_key=ab3efc5870&sti=rgbp.
If participants are unable to attend the event in person on the conference day, a recorded broadcast will also be accessible on EmergingGrowth.com.
Information on the Rising Development Conference
The Emerging Growth conference provides a convenient and efficient platform for public companies to showcase and convey important updates on their latest offerings, services, and other significant news to the investment community, all without leaving their office space.
The blog section covers various industries that are experiencing growth, featuring companies with capable leaders, groundbreaking offerings, a clear strategy, effective implementation, and the potential for sustained progress. Its readership comprises potentially a large number of individual and institutional investors, along with investment advisors and analysts.
Regen BioPharma Inc. is an organization that focuses on developing innovative solutions in the field of biotechnology.
Regen BioPharma, Inc. is a biotech company that is listed on the stock market as (PINK: RGBP) and (PINK: RGBPP). The company specializes in the field of immunology and immunotherapy. Their main goal is to quickly progress new technologies through experimental studies and initial clinical trials, particularly focusing on mRNA and small molecule therapies for cancer and autoimmune diseases. If you want to learn more about Regen BioPharma, you can visit their website at http://www.regenbiopharmainc.com.
Note: The following news update might include forecasts that may be uncertain. These predictions are vulnerable to risks and uncertainties, some of which cannot be determined or measured accurately. It is possible that future events and outcomes may significantly deviate from what is stated or implied in the forecasts. The risks and uncertainties that can impact such forward-looking statements include, but are not restricted to, government regulations, competition, and other significant risks.
How to Reach Us: If you need to get in touch with Regen BioPharma Inc, please feel free to contact our Chairman and Chief Executive Officer, Dr. David R. Koos. You can reach him at: Phone: +1-619-722-5505 Fax: +1-619-330-2328 Email: [email protected]
Stay connected with us on Twitter to receive the latest updates: https://twitter.com/TheRegenBio
Regen BioPharma Incorporated brings forth a vast array of expertly crafted pharmaceutical products.
